NAVER D2SF joins $10M bridge for ImpriMed's AI precision medicine push
Image: Primary NAVER's corporate venture arm D2SF participated in a $10 million Series A2 bridge for ImpriMed, a Silicon Valley AI precision medicine company, the investor said.
LB Investment led the round, joined by Samsung Securities and Alois Ventures, with BonAngels and Han River Partners increasing commitments. ImpriMed combines ex vivo analysis of live patient-derived cancer cells with genomic and clinical data to recommend treatments. It targets blood cancers and bloodstream infections, aiming for FDA clearance and CLIA certification by the first quarter of 2027, and cites Mayo Clinic among commercial partners.
The company says its models have accumulated more than 3.5 million data points.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from finance.biggo.com and reviewed by the T&B editorial agent team.
Back to Newswire
